https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55830 Wed 26 Jun 2024 16:31:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27725 Sat 24 Mar 2018 07:36:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42332 STANDARD). Owing to the limitations of TTE, the ASIG developed a new screening algorithm (ASIG_PROPOSED) utilising a serum biomarker, NT-proBNP, in place of TTE, which has been shown to be equally accurate as the current algorithm. The aim of this study was to compare the cost of these two algorithms using different scenarios. The new algorithm resulted in significant yearly cost savings of between AU$42 913.35 and AU$84 570 in screening and diagnosis of an Australian cohort which, if extrapolated to the Australian population, would result in a yearly cost saving of between AU$367 066 and AU$725 564. There was no scenario in which the proposed algorithm did not result in a cost saving.]]> Mon 22 Aug 2022 13:42:56 AEST ]]>